Huron Consulting Group Balances Growth, AI and Leverage

Huron Consulting Group ((HURN)) has held its Q1 earnings call. Read on for the main highlights of the call.

Huron Consulting Group’s latest earnings call struck a broadly upbeat tone as management highlighted double‑digit revenue growth, margin expansion, and record results in its core health care business. Leaders acknowledged pressure from heavy Q1 cash outflows, higher leverage, and softer digital revenue, but expressed confidence that strong bookings and AI‑driven demand will support the reaffirmed full‑year outlook.

Broad-Based Revenue Growth Across Segments

Huron reported revenues before reimbursable expenses of $443.7 million for Q1 2026, a 12.1% increase from $395.7 million a year earlier. Growth was described as well balanced, with health care, education, and commercial all contributing, underscoring the resilience of the firm’s diversified consulting portfolio.

Record Quarter in Health Care Consulting

The health care segment delivered record RBR of $225.2 million, rising 13.5% year over year and supported by 10% organic growth. Management emphasized strong demand for performance improvement and transformation work with large health systems, reinforcing health care as the company’s primary earnings engine.

Commercial and Education Businesses Gain Momentum

Commercial RBR surged 22.3% to $91.0 million, with acquisitions adding $11.0 million and broad demand for advisory and technology services. Education posted more modest RBR growth of 3.8% to $127.5 million, but notable margin gains suggested improved pricing, mix, and utilization in that segment.

Margins Expand as Profitability Improves

Adjusted EBITDA climbed to $50.6 million, or 11.4% of RBR, up from $41.5 million and 10.5% a year earlier, reflecting better operating leverage. Segment margins improved in education to 21.6% from 18.8% and in commercial to 16.4% from 15.2%, while health care margins remained robust at 28.4%.

Bookings, Backlog, and Pipeline Reach Strong Levels

Management highlighted that bookings over the trailing six months were up more than 20% across all three segments, citing broad‑based client appetite. Backlog now provides historically high coverage ratios and the pipeline sits near record levels, giving executives visibility and confidence in sustaining growth through 2026.

Guidance Reaffirmed on Strong Start to the Year

The company reaffirmed its 2026 outlook, calling for RBR between $1.78 billion and $1.86 billion and adjusted EBITDA margins of 14.5% to 15.0%. Adjusted non‑GAAP diluted EPS guidance of $8.35 to $9.15 was also maintained, signaling that Q1 trends support the prior full‑year earnings framework.

Shareholder Returns Through Aggressive Buybacks

Huron continued to return capital aggressively, repurchasing about $155.5 million of stock in Q1, or roughly 1.1 million shares, equal to 6.5% of shares outstanding at the start of the year. Since late 2022, the firm has bought back about 5 million shares, representing around 25% of its common stock, underscoring a strong shareholder‑return orientation.

AI and Digital Capabilities at the Strategic Core

Management framed artificial intelligence as a secular double‑digit growth opportunity and detailed ongoing investment in AI and digital capabilities. With roughly 40% of the business historically tied to technology and digital talent, the firm believes it is well positioned to capture AI‑driven demand across health care, education, and commercial clients.

Negative Free Cash Flow Driven by Seasonal Outflows

Operating cash flow was a use of $162.2 million in Q1 2026 and free cash flow was negative $174.1 million, compared with a sizable outflow a year earlier, largely due to annual incentive payments and capital spending. Management framed these cash swings as seasonal and expected, though they contributed to a temporary step‑up in leverage and reduced liquidity.

Leverage Rises but Deleveraging Plans in Place

Total debt stood at $856.0 million with cash of $26.5 million, resulting in net debt of $829.5 million and a leverage ratio of 3.1x adjusted EBITDA, up from 2.2x a year ago. Executives said leverage is typically highest in Q1 due to bonus payments and signaled an intent to bring leverage down toward the low‑two times range by year‑end.

Corporate Costs Move Higher

Unallocated corporate expenses, excluding restructuring, rose to $60.0 million from $52.4 million in the prior‑year quarter, driven by higher support staff compensation and increased software and data hosting costs. While these investments support growth and digital initiatives, they offset some of the margin gains achieved at the segment level.

DSO and Billing Timing Effects

Days sales outstanding increased to 82 days from 79 days a year ago and 73 days in Q4 2025, a move tied to several large health care projects with performance‑based fees. Management indicated that these arrangements are expected to bill and collect later in 2026, framing the DSO uptick as timing related rather than a structural credit issue.

Stable Net Income Amid Tax Rate Swings

Net income for Q1 2026 was $23.2 million, or $1.34 per diluted share, slightly below the prior‑year’s $24.5 million and $1.33 per share despite stronger revenues. The effective tax rate rose to 14.1% from a negative 14.4% a year earlier, and management reiterated a full‑year tax rate expectation of 28% to 30%, implying some earnings variability from tax timing.

Digital Revenue Softness Seen as Temporary

Digital revenue declined 7% in health care and mid‑single digits in commercial, reflecting timing delays and client budget dynamics rather than lost demand, according to management. The company expects digital growth to normalize and return to mid‑ to upper‑single‑digit rates in coming quarters as delayed projects ramp and AI‑related work scales.

Share Price Decline Prompted Faster Buybacks

Executives acknowledged that the company accelerated repurchases in Q1 partly in response to a decline in the share price, seeing the stock as undervalued. They cautioned that the pace of buybacks is likely to slow going forward as capital allocation shifts toward deleveraging goals and continued selective acquisitions.

Seasonality and Project Timing Weigh on Q1

Management reiterated that Q1 is seasonally the most challenging quarter for leverage and cash flow due to annual bonus payouts and other timing factors. Some digital projects also started later in the quarter than anticipated, impacting revenue timing and utilization, but these were portrayed as transitory rather than structural demand issues.

Guidance and Outlook Emphasize Growth and Deleveraging

Looking ahead, Huron expects full‑year RBR of $1.78 billion to $1.86 billion and adjusted EBITDA margins between 14.5% and 15.0%, reinforced by strong backlog and pipeline. The company is targeting positive free cash flow of $180 million to $220 million and a year‑end leverage ratio of 2.0x to 2.5x, while continuing disciplined tuck‑in M&A and measured share repurchases.

Huron’s earnings call painted a picture of a consulting firm riding strong demand, particularly in health care, while navigating the costs of growth, seasonality, and heavy capital returns. Investors will be watching whether management can deliver on its cash flow and deleveraging goals even as it leans into AI and digital investments, but the reaffirmed guidance suggests leadership remains confident in the company’s trajectory.